RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 13, 2016

Primary Completion Date

November 23, 2018

Study Completion Date

June 1, 2026

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

RNR inhibitor COH29

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

City of Hope Medical Center, Duarte

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER